Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney, with provisions for a live webcast for those unable to attend in person. The AGM will address the company’s financial statements and include a resolution on the adoption of the Remuneration Report, which is advisory and non-binding, reflecting the company’s commitment to transparency and shareholder engagement.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a biotechnology company based in Sydney, Australia, focusing on the development of immunotherapy treatments for cancer and autoimmune diseases. The company is known for its innovative approach in leveraging the body’s immune system to fight diseases, positioning itself as a leader in the biotech industry.
Average Trading Volume: 2,429,062
Technical Sentiment Signal: Buy
Current Market Cap: A$448.9M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.